General
Preferred name
BUCLIZINE
Synonyms
UCB-4445 ()
Longifene ()
Buclina ()
Buclizine HCl ()
Buclizine (dihydrochloride) ()
BUCLIZINE HYDROCHLORIDE ()
Bucladin-S ()
NSC-25141 ()
UCB 4445 ()
Buclodin ()
Equivert ()
Softran ()
Aphilan ()
Buclizine dihydrochloride ()
Bucladin ()
Buclizine (hydrochloride) ()
P&D ID
PD010084
CAS
129-74-8
82-95-1
Tags
available
drug
Approved by
FDA
Drug Status
approved
withdrawn
Drug indication
Antinauseant
Nausea
Max Phase
Phase 4
First approval
1982
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Buclizine is a piperazine derivative antihistamine and anticholinergic drug, with antiemetic properties.
(GtoPdb)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Compound Sets
17
Cayman Chemical Bioactives
ChEMBL Approved Drugs
ChEMBL Drugs
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
DrugMatrix
Guide to Pharmacology
MedChem Express Bioactive Compound Library
NPC Screening Collection
Other bioactive compounds
ReFrame library
TargetMol Bioactive Compound Library
Withdrawn 2.0
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
52
Molecular Weight
432.23
Hydrogen Bond Acceptors
2
Hydrogen Bond Donors
0
Rotatable Bonds
5
Ring Count
4
Aromatic Ring Count
3
cLogP
6.54
TPSA
6.48
Fraction CSP3
0.36
Chiral centers
1.0
Largest ring
6.0
QED
0.45
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Pathway
GPCR/G protein
Neuroscience
Immunology/Inflammation
Neuronal Signaling
Target
HT
Cholinergic
Histamine Receptor
ATC
R06AE01
Therapeutic Class
Antihistamines
Source data
